Want to see AU:BIO full AI Analyst Report?
Top Page
Biome Australia Ltd
(Sydney:BIO)
Select Model
Select Model
Rating:65Neutral
Price Target:
AU$0.36
▲(26.79% Upside)
Action:Reiterated
Date:08/28/26
The score is primarily driven by improving fundamentals—rapid revenue growth and a meaningful shift to profitability and positive free cash flow in 2026—tempered by historical volatility and rising debt. Technicals are mixed with only modest momentum, and valuation is moderate with no dividend yield support.
Positive Factors
Rapid Revenue Scaling
Sustained multi-year revenue expansion indicates strong commercial traction and growing product adoption. A larger revenue base can improve operating leverage and support broader distribution, provided growth remains efficient and repeat purchasing continues.
Negative Factors
Cash Flow Instability
The recent cash-flow improvement has not yet demonstrated durability because it follows several years of cash burn, including a large outflow in 2025. Continued volatility could constrain investment and increase dependence on financing if growth consumes cash again.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Scaling
Sustained multi-year revenue expansion indicates strong commercial traction and growing product adoption. A larger revenue base can improve operating leverage and support broader distribution, provided growth remains efficient and repeat purchasing continues.
Read all positive factors
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$63.84M
Dividend YieldN/A
Average Volume (3M)278.69K
Price to Earnings (P/E)20.8
Beta (1Y)1.01
Revenue Growth29.68%
EPS Growth1520.00%
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.02
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.31
Price to Sales (P/S)2.48
P/FCF Ratio41.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside167.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$33.00M
Biome Australia Ltd Business Overview & Revenue Model
Company Description
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line feat...
How the Company Makes Money
Biome Australia makes money primarily by selling probiotic and microbiome-related health products. Key revenue streams typically include (1) direct product sales to consumers via the company’s online/direct-to-consumer channels where Biome capture...
Biome Australia Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
63
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.88M | 18.42M | 13.01M | 7.24M | 4.11M |
| Gross Profit | 6.74M | 11.26M | 7.91M | 4.06M | 2.38M |
| EBITDA | 2.15M | 143.57K | -1.58M | -3.15M | -4.65M |
| Net Income | 3.61M | 214.66K | -1.67M | -3.08M | -4.54M |
Balance Sheet | |||||
| Total Assets | 15.72M | 11.97M | 8.28M | 7.56M | 8.25M |
| Cash, Cash Equivalents and Short-Term Investments | 3.55M | 2.75M | 2.87M | 2.26M | 5.49M |
| Total Debt | 2.97M | 3.07M | 1.30M | 1.15M | 467.05K |
| Total Liabilities | 6.34M | 7.29M | 5.37M | 3.97M | 1.73M |
| Stockholders Equity | 9.38M | 4.68M | 2.90M | 3.59M | 6.53M |
Cash Flow | |||||
| Free Cash Flow | 1.42M | -2.86M | -185.41K | -3.90M | -3.55M |
| Operating Cash Flow | 1.63M | -2.82M | -163.81K | -3.50M | -3.42M |
| Investing Cash Flow | -488.71K | -200.38K | -21.61K | -400.94K | -99.34K |
| Financing Cash Flow | -333.48K | 2.90M | 793.17K | 665.21K | 8.40M |
Biome Australia Ltd Technical Analysis
Positive
0.28
Price Trends
0.27
Positive
0.28
Positive
0.35
Negative
Market Momentum
>-0.01
Positive
52.44
Neutral
38.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.27, and below the 200-day MA of 0.35, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BIO.
Biome Australia Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$63.84M | 20.81 | 17.85% | ― | 29.68% | 1520.00% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$88.87M | -25.00 | -258.19% | ― | -46.59% | 9.09% | |
52 Neutral | AU$13.56M | -1.98 | -43.95% | ― | 14.30% | 41.93% | |
44 Neutral | AU$2.84M | -2.65 | -101.34% | ― | ― | 64.58% | |
44 Neutral | AU$74.95M | -10.34 | -41.83% | ― | -100.00% | 14.71% | |
38 Underperform | AU$116.19M | -3.31 | 279.21% | ― | ― | -37.23% |
* Consumer Defensive Sector Average
AU:BIO
Biome Australia Ltd
0.33
-0.21
-38.89%
AU:IMC
Immuron Limited
0.04
-0.03
-46.38%
AU:AVE
Avecho Biotechnology Limited
0.03
0.02
150.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.38
-0.04
-10.71%
AU:ALA
Arovella Therapeutics Limited
0.06
-0.03
-31.46%
Biome Australia Ltd Corporate Events
Biome Australia signs exclusive China e-commerce deal for Activated Probiotics
Aug 27, 2026
Biome Australia has signed an exclusive three-year cross-border e-commerce distribution heads of agreement with HS Global to launch its Activated Probiotics range in China, leveraging China’s status as the world’s largest single-countr...
Biome Australia posts record sales as Biome Daily tops probiotic market
Jul 28, 2026
Biome Australia has cemented its position in the microbiome health sector, reporting that Biome Daily is now the top-selling probiotic in Australian pharmacies by both units and value. The company’s Activated Probiotics and Activated Therape...
Biome Australia Sets FY27 Priorities After FY26 International Markets Review
Jul 27, 2026
Biome Australia has released an investor update reviewing its FY26 international market performance and outlining priorities for FY27, signalling a continued push into offshore markets and a focus on margin and manufacturing efficiency. The compan...
Biome Australia to brief investors on Q4 results and global expansion
Jul 26, 2026
Biome Australia Ltd will host an investor webinar on 3 August 2026 to discuss its Q4 FY26 quarterly results and a detailed update on international markets. The session, led by the founder and CFO, is designed to brief investors ahead of the releas...
Biome Australia Director Increases Equity Stake via On-Market Share Purchase
Jun 25, 2026
Biome Australia Limited has disclosed a change in director Blair Vega Norfolk’s interests, with Norfolk directly acquiring an additional 100,000 fully paid ordinary shares in an on-market purchase valued at about $25,030. Following this tran...
Biome Australia Director Increases Direct Shareholding via On-Market Purchase
Jun 3, 2026
Biome Australia director Blair Vega Norfolk has increased their direct holding in the company through an on-market purchase of 102,000 fully paid ordinary shares. The transaction, completed on 3 June 2026 for approximately $26,840, lifts Norfolk&#...
Biome Australia Highlights Growth and Profitability in H1 FY26 Update
Jun 2, 2026
Biome Australia reported its H1 FY26 results alongside a company presentation that underscores its status as Australia’s fastest-growing probiotic brand. The business highlights that it is clinically backed, profitable, and in a scaling phas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.